Five-year analysis from the ESPRIT 10-year postmarketing surveillance registry of adalimumab treatment for moderate to severe psoriasis A portion of the data in this manuscript was presented in at the Fall European Academy of Dermatology and Venereology 23rd Congress in Amsterdam on October 8, 2014.

Alan Menter*, Diamant Thaçi, Kim A. Papp, Jashin J. Wu, Mareike Bereswill, Henrique D. Teixeira, Simone Rubant, David A. Williams

*Corresponding author for this work
57   Link opens in a new tab Citations (Scopus)

Fingerprint

Dive into the research topics of 'Five-year analysis from the ESPRIT 10-year postmarketing surveillance registry of adalimumab treatment for moderate to severe psoriasis A portion of the data in this manuscript was presented in at the Fall European Academy of Dermatology and Venereology 23rd Congress in Amsterdam on October 8, 2014.'. Together they form a unique fingerprint.
Sort by

Pharmacology, Toxicology and Pharmaceutical Science

Medicine and Dentistry